Neoadjuvant programmed death-1 blockade plus chemotherapy in locally advanced esophageal squamous cell carcinoma
Authors:
- Guozhen YangGYGuozhen Yang
- Xiaodong SuXSXiaodong Su
- Hong YangHYHong Yang
- Guangyu LuoGLGuangyu Luo
- Chan GaoCGChan Gao
- Yating ZhengYZYating Zheng
- Wenzhuan XieWXWenzhuan Xie
- Mengli HuangMHMengli Huang
- Ting BeiTBTing Bei
- Yuezong BaiYBYuezong Bai
- Zhiqiang WangZWZhiqiang Wang
- Peiqiang CaiPCPeiqiang Cai
Open Access
- 1 August 2021
- journal article
- research article
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 9 (15) , 1254
Abstract
Background: Immunotherapy is effective in treating unresectable esophageal squamous cell carcinoma (ESCC), but little is known about its role in the preoperative setting. The aim of this study was to evaluate the safety, feasibility and efficacy of neoadjuvant treatment with camrelizumab plus chemotherapy in locally advanced ESCC. Methods: Patients diagnosed with locally advanced ESCC were retrospectively included if they had received neoadjuvant camrelizumab plus nab-paclitaxel and S1 capsule followed by radical esophagectomy between November, 2019 and June, 2020 at Sun Yat-sen University Cancer Center. Primary endpoints were safety and feasibility. In addition, pathological response and the relationship between tumor immune microenvironment (TIME)/tumor mutational burden (TMB) and treatment response were also investigated. Results: Twelve patients were included and they all received three courses of preoperative treatment with camrelizumab plus nab-paclitaxel/S1. No grade 3 or higher toxicities occurred. No surgical delay or perioperative death was reported. Nine patients (75%) responded to the treatment, four with a complete pathological response (pCR) and five with a major pathological response (MPR). Neither programmed death-ligand 1 (PD-L1) expression nor TMB was correlated with treatment response. TIME analysis revealed that a higher abundance of CD56dim natural killer cells was associated with better pathological response in the primary tumor, while lower density of M2-tumor-associated macrophages was associated with better pathological response in the lymph nodes (LNs). Conclusions: Neoadjuvant camrelizumab plus nab-paclitaxel and S1 is safe, feasible and effective in locally advanced ESCC and is worth further investigation.Keywords
This publication has 24 references indexed in Scilit:
- Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in OncologyJournal of the National Comprehensive Cancer Network, 2019
- Multi-institutional Analysis of Recurrence and Survival After Neoadjuvant Chemoradiotherapy of Esophageal CancerAnnals of Surgery, 2019
- Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaNature Medicine, 2018
- Epidemiology of Esophageal Squamous Cell CarcinomaGastroenterology, 2018
- Tumor and Microenvironment Evolution during Immunotherapy with NivolumabCell, 2017
- CD56bright NK cells exhibit potent antitumor responses following IL-15 primingJournal of Clinical Investigation, 2017
- High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methodsJournal of Experimental & Clinical Cancer Research, 2017
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Toxicity of platinum compoundsExpert Opinion on Pharmacotherapy, 2003
- Preoperative Adjuvant Radiochemotherapy May Increase the Risk in Patients Undergoing Thoracoabdominal Esophageal ResectionsDigestive Surgery, 2001